Mainz Biomed NV Financials
This page shows Mainz Biomed NV (MYNZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Mainz Biomed remains a cash-funded development company where research spend and financing access matter more than sales.
Revenue fell39.9% while free cash burn improved to-$11.0M ; that combination says the narrower loss came mainly from spending restraint, not commercial scaling. Because financing brought in only$6.8M , the burn still left cash at$889K and made short-term liquidity materially tighter.
A gross margin of
The rise in debt-to-equity reflects equity erosion more than heavier obligations: liabilities ended FY2025 at
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Mainz Biomed NV's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Mainz Biomed NV has an operating margin of -3005.0%, meaning the company retains $-3005 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2099.9% the prior year.
Mainz Biomed NV's revenue declined 39.9% year-over-year, from $894K to $537K. This contraction results in a growth score of 0/100.
Mainz Biomed NV has elevated debt relative to equity (D/E of 7.30), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Mainz Biomed NV's current ratio of 0.50 is below the typical benchmark, resulting in a score of 4/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While Mainz Biomed NV generated -$11.0M in operating cash flow, capex of $1K consumed most of it, leaving -$11.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Mainz Biomed NV generates a -2526.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -360.1% the prior year.
Mainz Biomed NV passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Mainz Biomed NV generates $0.68 in operating cash flow (-$11.0M OCF vs -$16.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Mainz Biomed NV earns $-43.2 in operating income for every $1 of interest expense (-$16.1M vs $373K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Mainz Biomed NV generated $537K in revenue in fiscal year 2025. This represents a decrease of 39.9% from the prior year.
Mainz Biomed NV's EBITDA was -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.1% from the prior year.
Mainz Biomed NV reported -$16.2M in net income in fiscal year 2025. This represents an increase of 24.9% from the prior year.
Mainz Biomed NV earned $-2.70 per diluted share (EPS) in fiscal year 2025. This represents an increase of 87.7% from the prior year.
Cash & Balance Sheet
Mainz Biomed NV generated -$11.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 37.0% from the prior year.
Mainz Biomed NV held $889K in cash against $0 in long-term debt as of fiscal year 2025.
Mainz Biomed NV had 10M shares outstanding in fiscal year 2025. This represents an increase of 321.7% from the prior year.
Margins & Returns
Mainz Biomed NV's gross margin was 72.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 8.3 percentage points from the prior year.
Mainz Biomed NV's operating margin was -3005.0% in fiscal year 2025, reflecting core business profitability. This is down 905.0 percentage points from the prior year.
Mainz Biomed NV's net profit margin was -3018.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 602.3 percentage points from the prior year.
Mainz Biomed NV's ROE was -2526.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2166.5 percentage points from the prior year.
Capital Allocation
Mainz Biomed NV invested $4.9M in research and development in fiscal year 2025. This represents a decrease of 14.2% from the prior year.
Mainz Biomed NV invested $1K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 98.8% from the prior year.
MYNZ Income Statement
| Metric | Q4'25 | Q4'24 | Q1'23 |
|---|---|---|---|
| Revenue | N/A | N/A | $1 |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | $1.6M |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
MYNZ Balance Sheet
| Metric | Q4'25 | Q4'24 | Q1'23 |
|---|---|---|---|
| Total Assets | $5.3M-60.5% | $13.5M | N/A |
| Current Assets | $1.8M-77.0% | $8.0M | N/A |
| Cash & Equivalents | $889K-85.7% | $6.2M | N/A |
| Inventory | $217K-41.8% | $373K | N/A |
| Accounts Receivable | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $4.7M-37.6% | $7.5M | N/A |
| Current Liabilities | $3.7M-40.3% | $6.2M | N/A |
| Long-Term Debt | N/A | N/A | N/A |
| Total Equity | $642K-89.3% | $6.0M | N/A |
| Retained Earnings | -$104.9M-18.3% | -$88.7M | N/A |
MYNZ Cash Flow Statement
| Metric | Q4'25 | Q4'24 | Q1'23 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
MYNZ Financial Ratios
| Metric | Q4'25 | Q4'24 | Q1'23 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 0.50-0.8 | 1.30 | N/A |
| Debt-to-Equity | 7.30+6.1 | 1.25 | N/A |
| FCF Margin | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Mainz Biomed NV's annual revenue?
Mainz Biomed NV (MYNZ) reported $537K in total revenue for fiscal year 2025. This represents a -39.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mainz Biomed NV's revenue growing?
Mainz Biomed NV (MYNZ) revenue declined by 39.9% year-over-year, from $894K to $537K in fiscal year 2025.
Is Mainz Biomed NV profitable?
No, Mainz Biomed NV (MYNZ) reported a net income of -$16.2M in fiscal year 2025, with a net profit margin of -3018.3%.
What is Mainz Biomed NV's EBITDA?
Mainz Biomed NV (MYNZ) had EBITDA of -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mainz Biomed NV's gross margin?
Mainz Biomed NV (MYNZ) had a gross margin of 72.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mainz Biomed NV's operating margin?
Mainz Biomed NV (MYNZ) had an operating margin of -3005.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Mainz Biomed NV's net profit margin?
Mainz Biomed NV (MYNZ) had a net profit margin of -3018.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Mainz Biomed NV's return on equity (ROE)?
Mainz Biomed NV (MYNZ) has a return on equity of -2526.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Mainz Biomed NV's free cash flow?
Mainz Biomed NV (MYNZ) generated -$11.0M in free cash flow during fiscal year 2025. This represents a 37.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mainz Biomed NV's operating cash flow?
Mainz Biomed NV (MYNZ) generated -$11.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Mainz Biomed NV's total assets?
Mainz Biomed NV (MYNZ) had $5.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Mainz Biomed NV's capital expenditures?
Mainz Biomed NV (MYNZ) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Mainz Biomed NV spend on research and development?
Mainz Biomed NV (MYNZ) invested $4.9M in research and development during fiscal year 2025.
What is Mainz Biomed NV's current ratio?
Mainz Biomed NV (MYNZ) had a current ratio of 0.50 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Mainz Biomed NV's debt-to-equity ratio?
Mainz Biomed NV (MYNZ) had a debt-to-equity ratio of 7.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mainz Biomed NV's return on assets (ROA)?
Mainz Biomed NV (MYNZ) had a return on assets of -304.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Mainz Biomed NV's cash runway?
Based on fiscal year 2025 data, Mainz Biomed NV (MYNZ) had $889K in cash against an annual operating cash burn of $11.0M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Mainz Biomed NV's Piotroski F-Score?
Mainz Biomed NV (MYNZ) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mainz Biomed NV's earnings high quality?
Mainz Biomed NV (MYNZ) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mainz Biomed NV cover its interest payments?
Mainz Biomed NV (MYNZ) has an interest coverage ratio of -43.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mainz Biomed NV?
Mainz Biomed NV (MYNZ) scores 1 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.